ストックスクリーナーアプリを入手
675.19
0.45%
3.04
アフターアワーズ：
694.28
19.09
+2.83%
前日終値:
$672.15
開ける：
$672.55
24時間の取引高:
529.24K
Relative Volume:
0.55
時価総額：
$70.79B
収益：
$14.92B
当期純損益:
$4.42B
株価収益率:
16.45
EPS:
41.0422
ネットキャッシュフロー:
$3.79B
1週間 パフォーマンス:
+2.91%
1か月 パフォーマンス:
+10.70%
6か月 パフォーマンス:
-9.89%
1年 パフォーマンス:
+23.77%
1日の値動き範囲:
$666.87
$678.67
1週間の範囲:
$648.66
$691.13
52週間の値動き範囲:
$541.00
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
名前
Regeneron Pharmaceuticals Inc
セクター
電話
(914) 847-7000
住所
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
675.19 | 70.47B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
482.00 | 121.95B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
874.74 | 52.94B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.29 | 38.35B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.37 | 36.40B | 4.29B | 577.22M | 641.34M | 4.2086 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-31 | 再開されました | Piper Sandler | Overweight |
| 2026-03-06 | 開始されました | Barclays | Overweight |
| 2026-01-07 | アップグレード | BofA Securities | Underperform → Buy |
| 2025-12-03 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | 開始されました | HSBC Securities | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Perform |
| 2025-08-14 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-06-30 | ダウングレード | Argus | Buy → Hold |
| 2025-05-30 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | アップグレード | Citigroup | Neutral → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-09-24 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 開始されました | Bernstein | Outperform |
| 2024-01-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 繰り返されました | Oppenheimer | Perform |
| 2023-06-28 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-23 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | アップグレード | Cowen | Market Perform → Outperform |
| 2023-01-20 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-26 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-09-09 | アップグレード | Jefferies | Underperform → Hold |
| 2022-09-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 開始されました | Jefferies | Underperform |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-01-03 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-12-07 | 再開されました | Cowen | Market Perform |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 再開されました | BMO Capital Markets | Outperform |
| 2021-11-05 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-01-25 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-01-08 | アップグレード | Citigroup | Neutral → Buy |
| 2020-10-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2020-07-09 | アップグレード | SunTrust | Hold → Buy |
| 2020-05-26 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-04-17 | アップグレード | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 開始されました | The Benchmark Company | Hold |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-02-26 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-11 | アップグレード | Argus | Hold → Buy |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-16 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-12-13 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Hold |
| 2019-11-07 | アップグレード | Citigroup | Neutral → Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
すべてを表示
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law - marketscreener.com
Lobbying Update: $630,000 of REGENERON PHARMACEUTICALS INC lobbying was just disclosed - Quiver Quantitative
REGN Maintained by Guggenheim -- Price Target Raised to $1000 - GuruFocus
REGN Investors Have Opportunity to Lead Regeneron - GlobeNewswire
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026REGN - PR Newswire
Regeneron stock holds its ground as sales and earnings stay strong - Ad-hoc-news.de
Telix Pharmaceuticals (TLX) hits US$247M Q2, inks Regeneron deal - Stock Titan
Telix Pharmaceuticals Limited and Regeneron Pharmaceuticals, Inc. Enter into Strategic Collaboration to Jointly Develop and Commercialize Next-Generation Radiopharmaceutical Therapies and Advance Multiple Novel Oncology Programs - marketscreener.com
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - GlobeNewswire Inc.
REGENERNON PHARMACEUTICALS, INC. (REGN) INVESTOR ALERT Investors With Large Losses in Regeneron Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - lincolnjournal.com
REGN Shareholder Alert: September 14, 2026 Lead Plaintiff - GlobeNewswire
Albany's construction sector signals growth from Regeneron's $2B expansion to rising contractor billings - MarketScale
Regeneron stock holds after 2025 revenue and earnings growth - Ad-hoc-news.de
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $965 From $968, Maintains Buy Rating - marketscreener.com
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - lincolnjournal.com
Regeneron Pharmaceuticals (REGN) Jefferies Global Healthcare Conference Summary - Quartr
Regeneron stock trades steady as Eylea and Dupixent growth support earnings - ad-hoc-news.de
Regeneron Pharmaceuticals, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – REGN - mykxlg.com
REGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026 - marketscreener.com
Regeneron stock trades near recent highs as Dupixent growth and pipeline updates support valuation - ad-hoc-news.de
Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod — Drug Pricing Deal With White House To Be Announced Today - Stocktwits
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
REGENERON ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Regeneron (REGN) Stock Looks Discounted As It Holds A 24% Gain - simplywall.st
REGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regeneron - GlobeNewswire
Regeneron Pharmaceuticals (REGN) Rebounds As Undervalued View Holds, Is The Upside Already Priced In? - Yahoo Finance
REGN Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. - PR Newswire
Regeneron stock trades steady as Eylea and Dupixent revenue support earnings trajectory - ad-hoc-news.de
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
Regeneron Investor Sues Over Cancer Drug Trial Miss, Stock Drops - Bloomberg Law News
Investor Notice: Robbins LLP Informs Investors of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit - Business Wire
Price-Driven Insight from (REGN) for Rule-Based Strategy - Stock Traders Daily
Regeneron Pharmaceuticals (Ondo Tokenized) price today, REGNON to USD live price, marketcap and chart - CoinDesk
Regeneron Pharmaceuticals (REGN) Stumbled In A Trial Setback, Is The Stock Still Cheap? - simplywall.st
Regeneron (REGN) Receives FDA Orphan Drug Designation for Dupilu - GuruFocus
Regeneron (REGN) Receives FDA Orphan Drug Designation for Dupilumab - GuruFocus
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Regeneron’s Drug Combo Fails To Prove Superiority Over Merck’s Keytruda In Melanoma - Stocktwits
Regeneron Pharmaceuticals (REGN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Regeneron stock holds firm as the focus shifts to the pipeline - Ad-hoc-news.de
Did Disappointing Trial Data Amid Strong Dupixent and Eylea Sales Just Shift Regeneron’s (REGN) Investment Narrative? - simplywall.st
Own Regeneron For Biotech Growth? Incyte Is Making Its Case. - Trefis
Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2 - Yahoo Finance
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $730 - Moomoo
Cantor Fitzgerald reiterates Overweight on Regeneron stock - Investing.com
BofA Securities Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $856 - Moomoo
Regeneron Pharmaceuticals (REGN): Investor Outlook On Its 23.77% Potential Upside - DirectorsTalk Interviews
Regeneron Cites Medtronic Ruling In Amgen Bundling Case - Law360
REGN Maintained by Piper Sandler -- Price Target Lowered to $854 - GuruFocus
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $854 - Moomoo
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $854 From $855 - Moomoo
Regeneron Pharmaceuticals Inc (REGN) 財務データ
収益
当期純利益
現金流量
EPS
3.37%
0.48%
大文字化:
|
ボリューム (24 時間):